CA3219760A1 - Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine - Google Patents
Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine Download PDFInfo
- Publication number
- CA3219760A1 CA3219760A1 CA3219760A CA3219760A CA3219760A1 CA 3219760 A1 CA3219760 A1 CA 3219760A1 CA 3219760 A CA3219760 A CA 3219760A CA 3219760 A CA3219760 A CA 3219760A CA 3219760 A1 CA3219760 A1 CA 3219760A1
- Authority
- CA
- Canada
- Prior art keywords
- count
- nadir
- baseline
- absolute neutrophil
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| US63/201,749 | 2021-05-11 | ||
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219760A1 true CA3219760A1 (en) | 2022-11-17 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219760A Pending CA3219760A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (https=) |
| EP (1) | EP4337183A4 (https=) |
| JP (1) | JP2024517318A (https=) |
| KR (1) | KR20240006659A (https=) |
| CN (1) | CN117642161A (https=) |
| AU (1) | AU2022273023A1 (https=) |
| BR (1) | BR112023023677A2 (https=) |
| CA (1) | CA3219760A1 (https=) |
| IL (1) | IL308321A (https=) |
| MX (1) | MX2023013364A (https=) |
| WO (1) | WO2022240786A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
| KR20220004669A (ko) * | 2019-04-29 | 2022-01-11 | 이뮤노젠 아이엔씨 | 항-cd123 면역접합체를 포함하는 치료적 조합물 |
| JP2022537551A (ja) * | 2019-06-20 | 2022-08-26 | セルジーン・クオンティセル・リサーチ・インコーポレイテッド | ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
-
2022
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022273023A1 (en) | 2023-11-23 |
| MX2023013364A (es) | 2023-11-27 |
| US20220378811A1 (en) | 2022-12-01 |
| EP4337183A4 (en) | 2025-04-23 |
| KR20240006659A (ko) | 2024-01-15 |
| WO2022240786A1 (en) | 2022-11-17 |
| EP4337183A1 (en) | 2024-03-20 |
| JP2024517318A (ja) | 2024-04-19 |
| IL308321A (en) | 2024-01-01 |
| CN117642161A (zh) | 2024-03-01 |
| BR112023023677A2 (pt) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Welschinger et al. | Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice | |
| JP2024167278A (ja) | Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法 | |
| US20260103532A1 (en) | Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereof | |
| US20140023661A1 (en) | Combination therapy | |
| KR20220080179A (ko) | (R)-2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴을 투여하여 면역 혈소판 감소증을 치료하는 방법 | |
| US20220370481A1 (en) | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine | |
| JP2024054143A (ja) | 抗ｐ－セレクチン抗体の使用 | |
| US20220378811A1 (en) | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine | |
| Bonaros et al. | Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation | |
| WO2025045766A1 (en) | Compositions comprising humanized anti-cd40 antibodies and methods for treating rheumatoid arthritis using the same | |
| Rodríguez | Management of the adverse effects of lenalidomide in multiple myeloma | |
| HK40106739A (zh) | 与阿扎胞苷联合用於治疗骨髓增生异常综合征的维奈托克给药方案 | |
| Chang et al. | Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study | |
| HK40106881A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| WO2025208442A1 (en) | Methods of treatment of immune thrombocytopenia using sovleplenib | |
| Elter et al. | Alemtuzumab: what is the secret to safe therapy | |
| WO2025209478A1 (en) | Methods of treatment warm autoimmune hemolytic anemia using sovleplenib | |
| WO2025040080A1 (en) | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy | |
| Tyler et al. | A Review of Therapeutics for the Treatment of Lupus | |
| WO2025122961A1 (en) | Methods for treating neutropenia | |
| TW202440120A (zh) | 藉由投予（ｒ）－２－［３－［４－胺基－３－（２－氟－４－苯氧基－苯基）吡唑并［３，４－ｄ］嘧啶－１－基］六氫吡啶－１－羰基］－４－甲基－４－［４－（氧雜環丁－３－基）六氫吡𠯤－１－基］戊－２－烯腈治療患有認知障礙的個體之免疫性血小板減少症之方法 | |
| HK40097470A (en) | Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia | |
| CN121358495A (zh) | 用于治疗系统性硬化症的免疫球蛋白制剂 | |
| Schmitt et al. | CLINICAL NEPHROLOGY-EPIDEMIOLOGY-CLINICAL TRIALS Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. | |
| HK40079147A (en) | Use of multi-target protein kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250409 |